FDA label f45d84fa-9959-6954-e053-2a95a90a41cd
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- 066ed2a0-d499-4749-9c96-3fc0a820677d
- SPL ID
- f45d84fa-9959-6954-e053-2a95a90a41cd
- Version
- 1
- Effective date
- 2023-02-10
- Source export date
- 2026-11-13
- Source partition
- 1
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/4245fd4310917b72c4a58c789d30a0b365e492ef46f48e107e3c3e16139b0499/drug-label-0001-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:27:09
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | f45d84fa-9959-6954-e053-2a95a90a41cd | id | |
| spl set id | 066ed2a0-d499-4749-9c96-3fc0a820677d | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Monitoring : Continuously monitor patients while receiving PRECEDEX. ( 5.1 ) Bradycardia and Sinus Arrest : Have occurred in young healthy volunteers with high vagal tone or with different routes of administration, e.g., rapid intravenous or bolus administration. ( 5.2 ) Hypotension and Bradycardia : May necessitate medical intervention. May be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension, and in the elderly. Use with caution in patients with advanced heart block or severe ventricular dysfunction. ( 5.2 ) Co-administration with Other Vasodilators or Negative Chronotropic Agents : Use with caution due to additive pharmacodynamic effects. ( 5.2 ) Transient Hypertension : Observed primarily during the loading dose. Consider reduction in loading infusion rate. ( 5.3 ) Arousability : Patients can become aroused/alert with stimulation; this alone should not be considered as lack of efficacy. ( 5.4 ) Tolerance and Tachyphylaxis : Prolonged exposure to dexmedetomidine beyond 24 hours may be associated with tolerance and tachyphylaxis and a dose-related increase in adverse events. ( 5.6 ) 5.1 Drug Administration PRECEDEX should be administered only by persons skilled in the management of patients in the intensive care or operating room setting. Due to the known pharmacological effects of PRECEDEX, patients should be continuously monitored while receiving PRECEDEX. 5.2 Hypotension, Bradycardia, and Sinus Arrest Clinically significant episodes of bradycardia and sinus arrest have been reported with PRECEDEX administration in young, healthy adult volunteers with high vagal tone or with different routes of administration including rapid intravenous or bolus administration. Reports of hypotension and bradycardia have been associated with PRECEDEX infusion. Some of these cases have resulted in fatalities. If medical intervention is required, treatment may include decreasing or stopping the infusion of PRECEDEX, increasing the rate of intravenous fluid administration, elevation of the lower extremities, and use of pressor agents. Because PRECEDEX has the potential to augment bradycardia induced by vagal stimuli, clinicians should be prepared to intervene. The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. In clinical trials, glycopyrrolate or atropine were effective in the treatment of most episodes of PRECEDEX-induced bradycardia. However, in some patients with significant cardiovascular dysfunction, more advanced resuscitative measures were required. Caution should be exercised when administering PRECEDEX to patients with advanced heart block and/or severe ventricular dysfunction. Because PRECEDEX decreases sympathetic nervous system activity, hypotension and/or bradycardia may be expected to be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension and in elderly patients. In clinical trials where other vasodilators or negative chronotropic agents were co-administered with PRECEDEX an additive pharmacodynamic effect was not observed. Nonetheless, caution should be used when such agents are administered concomitantly with PRECEDEX. 5.3 Transient Hypertension Transient hypertension has been observed primarily during the loading dose in association with the initial peripheral vasoconstrictive effects of PRECEDEX. Treatment of the transient hypertension has generally not been necessary, although reduction of the loading infusion rate may be desirable. 5.4 Arousability Some patients receiving PRECEDEX have been observed to be arousable and alert when stimulated. This alone should not be considered as evidence of lack of efficacy in the absence of other clinical signs and symptoms. 5.5 Withdrawal Intensive Care Unit Sedation With administration up to 7 days, regardless of dose, 12 (5%) PRECEDEX adult subjects experienced at least 1 event related to withdrawal within the first 24 hours after discontinuing study drug and 7 (3%) PRECEDEX adult subjects experienced at least 1 event 24 to 48 hours after end of study drug. The most common events were nausea, vomiting, and agitation [see Adverse Reactions (6.1) ] . In adult subjects, tachycardia and hypertension requiring intervention in the 48 hours following study drug discontinuation occurred at frequencies of <5%. Procedural Sedation In adult subjects, withdrawal symptoms were not seen after discontinuation of short-term infusions of PRECEDEX (<6 hours). In pediatric patients, mild transient withdrawal symptoms of emergence delirium or agitation were seen after discontinuation of short‑term infusions of PRECEDEX (<2 hours) [see Adverse Reactions (6.1) ]. 5.6 Tolerance and Tachyphylaxis Use of dexmedetomidine beyond 24 hours has been associated with tolerance and tachyphylaxis and a dose-related increase in adverse reactions [see Adverse Reactions (6.1) ] . 5.7 Hyperthermia or Pyrexia PRECEDEX may induce hyperthermia or pyrexia, which may be resistant to traditional cooling methods, such as administration of cooled intravenous fluids and antipyretic medications. Discontinue PRECEDEX if drug-related hyperthermia or pyrexia is suspected and monitor patients until body temperature normalizes. 5.8 Hepatic Impairment Since PRECEDEX clearance decreases with severity of hepatic impairment, dose reduction should be considered in patients with impaired hepatic function [see Dosage and Administration (2.2 , 2.3) ] .
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions table
<table ID="TABLE6" width="90%"><caption>Table 5: Number (%) of Adult Subjects Who Had a Dose-Related Increase in Treatment Emergent Adverse Events by Maintenance Adjusted Dose Rate Range in the PRECEDEX Group</caption><col width="40%"/><col width="20%"/><col width="20%"/><col width="20%"/><thead><tr><th colspan="4" align="center" styleCode="Botrule Toprule" valign="top"><content styleCode="bold">PRECEDEX (mcg/kg/hr)</content></th></tr><tr><th align="left" styleCode="Botrule Rrule" valign="bottom"><content styleCode="bold">Adverse Event</content></th><th align="center" styleCode="Botrule Rrule" valign="top"><content styleCode="bold">≤0.7</content><footnote ID="_Ref125367372">Average maintenance dose over the entire study drug administration.</footnote> <content styleCode="bold"> (N = 95)</content></th><th align="center" styleCode="Botrule Rrule" valign="top"><content styleCode="bold">>0.7 to ≤1.1</content><footnoteRef IDREF="_Ref125367372"/> <content styleCode="bold"> (N = 78)</content></th><th align="center" styleCode="Botrule" valign="top"><content styleCode="bold">>1.1</content><footnoteRef IDREF="_Ref125367372"/> <content styleCode="bold"> (N = 71)</content></th></tr></thead><tbody><tr><td styleCode="Botrule Rrule Toprule" valign="top"><paragraph>Constipation</paragraph></td><td align="center" styleCode="Botrule Rrule Toprule" valign="top"><paragraph>6%</paragraph></td><td align="center" styleCode="Botrule Rrule Toprule" valign="top"><paragraph>5%</paragraph></td><td align="center" styleCode="Botrule Toprule" valign="top"><paragraph>14%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Agitation</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>5%</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>8%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>14%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Anxiety</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>5%</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>5%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>9%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Edema Peripheral</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>3%</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>5%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>7%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Atrial Fibrillation</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>4%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>9%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Respiratory Failure</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>6%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>10%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Acute Respiratory Distress Syndrome</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>1%</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>3%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>9%</paragraph></td></tr></tbody></table>
adverse reactions table
<table ID="TABLE7" width="90%"><caption>Table 6: Adverse Reactions with an Incidence >2%—Adult Procedural Sedation Population</caption><col width="34%"/><col width="33%"/><col width="33%"/><thead><tr styleCode="First Last"><th align="left" styleCode="Botrule Rrule Toprule" valign="bottom"><content styleCode="bold">Adverse Event</content></th><th align="center" styleCode="Botrule Rrule Toprule" valign="bottom"><content styleCode="bold">PRECEDEX</content> <content styleCode="bold"> (N = 318)</content> <content styleCode="bold"> (%)</content></th><th align="center" styleCode="Botrule Toprule" valign="bottom"><content styleCode="bold">Placebo</content> <content styleCode="bold"> (N = 113)</content> <content styleCode="bold"> (%)</content></th></tr></thead><tbody><tr><td styleCode="Botrule Rrule Toprule" valign="top"><paragraph>Hypotension <footnote ID="_RefID0EROBG">Hypotension was defined in absolute and relative terms as Systolic blood pressure of <80 mmHg or ≤30% lower than pre-study drug infusion value, or Diastolic blood pressure of <50 mmHg.</footnote></paragraph></td><td align="center" styleCode="Botrule Rrule Toprule" valign="top"><paragraph>54%</paragraph></td><td align="center" styleCode="Botrule Toprule" valign="top"><paragraph>30%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Respiratory Depression <footnote ID="_RefID0E1OBG">Respiratory depression was defined in absolute and relative terms as respiratory rate (RR) <8 beats per minute or >25% decrease from baseline.</footnote></paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>37%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>32%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Bradycardia <footnote ID="_RefID0EDPBG">Bradycardia was defined in absolute and relative terms as <40 beats per minute or ≤30% lower than pre-study drug infusion value. Subjects in Study 2 were pretreated with glycopyrrolate 0.1 mg intravenously before receiving study drug [see Clinical Studies (14.2)] . Subjects in Study 2 were pretreated with glycopyrrolate 0.1 mg intravenously before receiving study drug [see Clinical Studies (14.2)] . </footnote></paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>14%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>4%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Hypertension <footnote ID="_RefID0EMPBG">Hypertension was defined in absolute and relative terms as Systolic blood pressure >180 mmHg or ≥30% higher than pre-study drug infusion value or Diastolic blood pressure of >100 mmHg.</footnote></paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>13%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>24%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Tachycardia <footnote ID="_RefID0EVPBG">Tachycardia was defined in absolute and relative terms as >120 beats per minute or ≥30% greater than pre-study drug infusion value.</footnote></paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>5%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>17%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Nausea</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>3%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>2%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Dry Mouth</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>3%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>1%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Hypoxia <footnote ID="_RefID0EMQBG">Hypoxia was defined in absolute and relative terms as SpO 2 <90% or 10% decrease from baseline. </footnote></paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>3%</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Bradypnea</paragraph></td><td align="center" styleCode="Botrule Rrule" valign="top"><paragraph>2%</paragraph></td><td align="center" styleCode="Botrule" valign="top"><paragraph>4%</paragraph></td></tr></tbody></table>
adverse reactions table
<table width="90%"><caption>Table 7: Adverse Reactions Experienced During Post-Approval Use of PRECEDEX</caption><col width="35%"/><col width="65%"/><thead><tr styleCode="First Last"><th align="left" styleCode="Botrule Rrule Toprule" valign="top"><content styleCode="bold">System Organ Class</content></th><th align="left" styleCode="Botrule Toprule" valign="top"><content styleCode="bold">Preferred Term</content></th></tr></thead><tbody><tr><td styleCode="Botrule Rrule Toprule" valign="top"><paragraph>Blood and Lymphatic System Disorders</paragraph></td><td styleCode="Botrule Toprule" valign="top"><paragraph>Anemia</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Cardiac Disorders</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Arrhythmia, atrial fibrillation, atrioventricular block, bradycardia, cardiac arrest, cardiac disorder, extrasystoles, myocardial infarction, supraventricular tachycardia, tachycardia, ventricular arrhythmia, ventricular tachycardia</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Eye Disorders</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Photopsia, visual impairment</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Gastrointestinal Disorders</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Abdominal pain, diarrhea, nausea, vomiting</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>General Disorders and Administration Site Conditions</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Chills, hyperpyrexia, pain, pyrexia, thirst</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Hepatobiliary Disorders</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Hepatic function abnormal, hyperbilirubinemia</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Investigations</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood urea increased, electrocardiogram T wave inversion, gammaglutamyltransferase increased, electrocardiogram QT prolonged</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Metabolism and Nutrition Disorders</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Acidosis, hyperkalemia, hypoglycemia, hypovolemia, hypernatremia</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Nervous System Disorders</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Convulsion, dizziness, headache, neuralgia, neuritis, speech disorder</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Psychiatric Disorders</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Agitation, confusional state, delirium, hallucination, illusion</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Renal and Urinary Disorders</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Oliguria, polyuria</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Respiratory, Thoracic and Mediastinal Disorders</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Apnea, bronchospasm, dyspnea, hypercapnia, hypoventilation, hypoxia, pulmonary congestion, respiratory acidosis</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Skin and Subcutaneous Tissue Disorders</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Hyperhidrosis, pruritus, rash, urticaria</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Surgical and Medical Procedures</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Light anesthesia</paragraph></td></tr><tr><td styleCode="Botrule Rrule" valign="top"><paragraph>Vascular Disorders</paragraph></td><td styleCode="Botrule" valign="top"><paragraph>Blood pressure fluctuation, hemorrhage, hypertension, hypotension</paragraph></td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.